FDA Outlines Combination Contraceptive Labeling in New Draft Guidance

Drug Industry Daily
A A
A new FDA draft guidance recommends sponsors include new class labeling and prescribing information for combined hormonal contraceptives containing estrogen and progestin.

To View This Article:

Login

Subscribe To Drug Industry Daily